Comparison of oral montelukastwith oral ozagrel in sudden attack of asthma
- Conditions
- Health Condition 1: null- Acute exacerbation of Bronchial Asthma
- Registration Number
- CTRI/2016/10/007382
- Lead Sponsor
- Dr vyshak U S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 120
1.Age between 18 and 65.
2.Previously diagnosed case of bronchial asthma.
3.A primary diagnosis of acute exacerbation of asthma on presentation.
4.Peak expiratory flow rate (PEFR)less than or equal to 75% of personal best with in the last 12 months or of predicted value.
5.No other acute pathology complicating the present condition like cardiac,metabolic or other respiratory causes.
1.Smoking history more than 10 pack years.
2.Pregnant females and Breast feeding females.
3.Patient on regular Leukotriene receptor antagonists or thromboxane A2 synthetase inhibitor with in 2 weeks of presentation.
4.Intake of oral or parenteral steroids for > 5 days with in one month of presentation.
5.Intake of theophylline with in one week of presentation.
6.Need of intubation before presentation.
7.Patients on regular Rifampicin, Phenytoin or Phenobarbitone.
8. History of allergy to Montelukast or ozagrel.
9. Baseline renal function test and liver function test derangement.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage change in PEFR (Peak expiratory flow rate)from baseline.Timepoint: 6 hrs 12 hrs 24 hrs and 48 hrs following administration of study drug and at discharge.
- Secondary Outcome Measures
Name Time Method umber of times rescue medications were required.Timepoint: Any time from the administration of study drug to the time of discharge.